In yesterday’s Wall Street session, Immunic Inc. (NASDAQ:IMUX) shares traded at $2.32, up 4.04% from the previous session.
As of this writing, 4 analysts cover Immunic Inc. (NASDAQ:IMUX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $5.00, we find $10.00. Given the previous closing price of $2.23, this indicates a potential upside of 348.43 percent. IMUX stock price is now 25.55% away from the 50-day moving average and -29.07% away from the 200-day moving average. The market capitalization of the company currently stands at $105.65M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 3 have given it a buy rating. Brokers who have rated the stock have averaged $13.25 as their price target over the next twelve months.
With the price target maintained at $5, SVB Leerink recently Downgraded its rating from Outperform to Mkt Perform for Immunic Inc. (NASDAQ: IMUX)., while ‘Aegis Capital’ rates the stock as ‘Buy’.
In other news, Neermann Joerg, Director bought 47,000 shares of the company’s stock on Dec 14. The stock was bought for $59,032 at an average price of $1.26. Upon completion of the transaction, the Director now directly owns 100,000 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13, Director Neermann Joerg bought 35,000 shares of the business’s stock. A total of $43,610 was incurred on buying the stock at an average price of $1.25. This leaves the insider owning 53,000 shares of the company worth $0.12 million. Insiders disposed of 6,000 shares of company stock worth roughly $13919.999999999998 over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IMUX stock. A new stake in Immunic Inc. shares was purchased by BVF INC/IL during the first quarter worth $2,667,000. ANSON FUNDS MANAGEMENT LP invested $1,543,000 in shares of IMUX during the first quarter. In the first quarter, IKARIAN CAPITAL, LLC acquired a new stake in Immunic Inc. valued at approximately $1,508,000. GREAT POINT PARTNERS I LP acquired a new stake in IMUX for approximately $1,467,000. RA CAPITAL MANAGEMENT, L.P. purchased a new stake in IMUX valued at around $1,467,000 in the second quarter. In total, there are 88 active investors with 44.70% ownership of the company’s stock.
Tuesday morning saw Immunic Inc. (NASDAQ: IMUX) opened at $2.2100. During the past 12 months, Immunic Inc. has had a low of $1.11 and a high of $12.64. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.60, and a quick ratio of 9.60. The fifty day moving average price for IMUX is $1.8478 and a two-hundred day moving average price translates $3.2710 for the stock.
The latest earnings results from Immunic Inc. (NASDAQ: IMUX) was released for Sep, 2022.
Immunic Inc.(IMUX) Company Profile
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
